The technology and commercialisation journey of Evonetix

Add to your list(s) Download to your calendar using vCal

• Matthew Hayes, CTO Evonetix
• Friday 24 June 2022, 15:00-16:00
• Hybrid - Maxwell Centre & on Zoom.

If you have a question about this talk, please contact Samantha Selvini.

Evonetix started when a small team of 12 people span out of Cambridge Consultants in 2015, based on an idea that could revolutionise the manufacture of synthetic DNA . The company has since grown to over 100 people, raised more than $45million in capital, and proven the core technology.

Matt Hayes, one of the founding members as well as the company’s CTO and interim CEO , will share with you some of the highs and lows of that journey, along with some of the lessons he has learnt along the way.

About the speaker

Matthew Hayes is the Chief Technology Officer and current interim CEO of Evonetix, and was a founder member of the team that created the company in 2015.

Before joining Evonetix, Matthew was Head of Technology for the Global Medtech Division of Cambridge Consultants. He joined Cambridge Consultants in 2001, and was responsible for the leadership of many of their largest and most technically challenging projects.

Matthew specialises in multi-disciplinary system design, medical device development, ASIC design and opto-electronics. He holds a PhD and MEng in Electronic Engineering, both from Loughborough University.

Register here for this FREE talk: https://forms.gle/ydrVhQFv1DwkKadR8

Friday 24 June 3:00 – 4:00 pm

Hybrid event

JJ Thomson seminar room Maxwell Centre J Tomson ave, Cambridge CB3 0HE

Or join us on Zoom:

Zoom link: https://bit.ly/3OYswjg

Meeting ID: 815 2886 8878 Passcode: 818779 Find your local number: https://us06web.zoom.us/u/kb0WU1V4mi

This talk is part of the GAPSTI Science & Technology Distinguished Seminars Series series.

This talk is included in these lists:

• GAPSTI Science & Technology Distinguished Seminars Series
• Hybrid - Maxwell Centre & on Zoom

Note that ex-directory lists are not shown.